Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...

Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...

Novo Nordisk stock tumbled Monday after its experimental weight-loss drug failed to top its rival from Eli Lilly in a Phase 3 study.

Also, Novo Nordisk offers the possibility of viewing the Annual General Meeting via live webcast on Novo Nordisk's website. Please refer to the enclosed notice for the Annual General Meeting for ...

Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug Wegovy and diabetes treatment Ozempic without a fight. An industry group ...

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer. Hims & Hers Health Inc.’s stock plunged last week when the ...

Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to Novo Nordisk's Wegovy and Ozempic weight-loss drugs. Hims stock stood ...

AS Heart Month reminds us of the critical need to protect our cardiovascular and metabolic health, Novo Nordisk Philippines and the Philippine College of Endocrinology, Diabetes and Metabolism (PCEDM) ...

The drugmaker Novo Nordisk can meet current and future demand in the U.S., the Food and Drug Administration said. But patients may still see some supply disruptions as the medications move from ...

The U.S. Food and Drug Administration declared that the shortage of Novo Nordisk’s NOVO.B-3.02%decrease; red down pointing triangle weight-loss medications Wegovy and Ozempic has been resolved ...